PDF Cover

Glycerol Phenylbutyrate Liquid Market

The market for Glycerol Phenylbutyrate Liquid was estimated at $137 million in 2024; it is anticipated to increase to $474 million by 2030, with projections indicating growth to around $1.34 billion by 2035.

Report ID:DS1802094
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Glycerol Phenylbutyrate Liquid
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Glycerol Phenylbutyrate Liquid Market Outlook

Revenue, 2024

$137M

Forecast, 2034

$1.09B

CAGR, 2025 - 2034

23.0%

The Glycerol Phenylbutyrate Liquid industry revenue is expected to be around $168.5 million in 2025 and expected to showcase growth with 23.0% CAGR between 2025 and 2034. Building on this strong growth trajectory, the glycerol phenylbutyrate liquid market is gaining strategic importance within the rare disease therapeutics landscape, particularly for managing Urea Cycle Disorders. Its relevance is driven by increasing diagnosis rates, improved newborn screening programs, and greater clinical awareness across developed healthcare systems. Pharmaceutical companies are prioritizing patient-centric formulations that enhance compliance, especially in pediatric populations requiring long-term ammonia control. In addition, supportive regulatory frameworks and orphan drug incentives are encouraging continued investment and innovation. The market is also benefiting from expanded access programs and evolving reimbursement models, which are gradually improving treatment affordability. As a result, glycerol phenylbutyrate liquid is becoming a cornerstone therapy in metabolic disorder management, reinforcing its sustained clinical and commercial significance.

Glycerol phenylbutyrate liquid, also known as Ravicti, is a nitrogen-scavenging agent designed to help remove excess ammonia from the bloodstream in patients with inherited metabolic conditions. It offers advantages such as improved palatability, lower dosing frequency, and better gastrointestinal tolerability compared to older therapies like Sodium Phenylbutyrate. The drug is primarily used in chronic management settings, supporting both pediatric and adult patients. Key applications include long-term metabolic control and prevention of hyperammonemic crises. Recent trends shaping demand include the shift toward home-based care, increasing adoption of liquid formulations, and advancements in precision medicine for rare diseases. Additionally, ongoing clinical research and lifecycle management strategies are expanding its therapeutic potential and strengthening its role in specialized metabolic treatment protocols.

Glycerol Phenylbutyrate Liquid market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Glycerol Phenylbutyrate Liquid Market Outlook

Market Key Insights

  • The Glycerol Phenylbutyrate Liquid market is projected to grow from $137.0 million in 2024 to $1.09 billion in 2034. This represents a CAGR of 23%, reflecting rising demand across Urea Cycle Disorders Treatment, Hepatic Encephalopathy Management, and Research and Development.

  • This is a highly consolidated market with 3 key players, where Amgen holds the dominant share.

  • U.S. and Germany are the top markets within the Glycerol Phenylbutyrate Liquid market and are expected to observe the growth CAGR of 22.1% to 32.2% between 2024 and 2030.

  • Emerging markets including Brazil, South Africa and Malaysia are expected to observe highest growth with CAGR ranging between 17.3% to 23.9%.

  • The complete eco-system of the Glycerol Phenylbutyrate Liquid market is becoming more attractive for investment due to transitions such as Transition from single-originator dominance to emerging multi-player generic competition. These changes are expected to create a positive cycle that supports growth and adds an estimated $41 million in value between 2025 and 2030.

  • The Glycerol Phenylbutyrate Liquid market is set to add $949 million between 2024 and 2034, with manufacturer targeting Nutritional Supplements Application projected to gain a larger market share.

  • With

    growth in urea cycle disorders treatment, and

    Technological Advancements in Pharmaceutical Manufacturing, Glycerol Phenylbutyrate Liquid market to expand 693% between 2024 and 2034.

glycerol phenylbutyrate liquid market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Glycerol Phenylbutyrate Liquid - Country Share Analysis

Opportunities in the Glycerol Phenylbutyrate Liquid

A significant opportunity lies in expanding pediatric treatment access for Urea Cycle Disorders in emerging markets such as India, China, and Brazil. Increasing newborn screening adoption and improving diagnostic infrastructure are uncovering previously undiagnosed cases. Pediatric oral liquid formulations of glycerol phenylbutyrate are expected to see the highest growth due to ease of administration and long-term therapy suitability. Governments and NGOs are also supporting rare disease funding programs, improving affordability. Companies focusing on localized pricing strategies and partnerships with regional healthcare providers can tap into this underpenetrated, high-potential patient segment.

Growth Opportunities in North America and Asia-Pacific

North America remains the dominant regional market, driven by advanced healthcare infrastructure, strong orphan drug adoption, and high awareness of Urea Cycle Disorders. The region accounts for the largest revenue share globally due to favorable reimbursement frameworks and early diagnosis through newborn screening programs. A key driver is the presence of leading pharmaceutical companies and continuous lifecycle management strategies that sustain prescription volumes. Opportunities are emerging through expanded indications and patient support programs that improve adherence. However, competition is intensifying with the entry of generics, increasing payer negotiation power and pricing pressure. Despite this, strong clinical adoption, specialty care infrastructure, and high healthcare spending ensure continued market leadership and stable long-term growth.
Asia-Pacific is the fastest-growing region, supported by rising healthcare expenditure, improving diagnostic capabilities, and expanding access to rare disease treatments. Increasing awareness of metabolic disorders and gradual inclusion of rare diseases in national healthcare programs are key growth drivers. The region offers significant opportunities due to a large undiagnosed patient population and expanding hospital infrastructure. Countries such as China and India are witnessing improved regulatory approvals and market entry strategies by global players. However, competition from lower-cost alternatives and limited reimbursement coverage remain challenges. Overall, rapid urbanization, healthcare modernization, and growing demand for specialized therapies are expected to accelerate adoption and position Asia-Pacific as a critical growth engine for the glycerol phenylbutyrate liquid market.

Market Dynamics and Supply Chain

01

Driver: Rising urea cycle disorder diagnosis rates and expanding newborn screening programs globally

A major driver for glycerol phenylbutyrate liquid is also the simultaneous rise in diagnosis rates of Urea Cycle Disorders and the global expansion of newborn screening initiatives. Improved genetic testing technologies and early diagnostic protocols are also enabling faster and more accurate identification of metabolic disorders, particularly in developed healthcare systems. Governments and healthcare organizations are also increasingly mandating newborn screening panels that include rare metabolic conditions, leading to earlier intervention and long-term treatment initiation. This directly increases the patient pool requiring ammonia control therapies such as glycerol phenylbutyrate. Additionally, advancements in metabolic disorder registries and awareness campaigns are also reducing underdiagnosis in emerging markets. Together, these trends are also driving sustained demand for effective nitrogen-scavenging treatments and reinforcing the importance of early-stage disease management.
Another key driver is also the advancement of patient-centric drug formulations, particularly oral liquid therapies designed for chronic disease management. Glycerol phenylbutyrate offers improved palatability, lower dosing frequency, and better gastrointestinal tolerability compared to older alternatives like Sodium Phenylbutyrate. These formulation improvements are also especially critical in pediatric and geriatric populations, where adherence challenges are also more pronounced. Pharmaceutical innovation is also increasingly focused on enhancing drug delivery systems that simplify long-term therapy, reduce side effects, and improve quality of life. As a result, healthcare providers are also prioritizing such advanced formulations, driving higher prescription rates and strengthening market growth.
02

Restraint: High treatment costs and unfavorable cost-effectiveness limiting reimbursement and patient access globally

A major restraint for glycerol phenylbutyrate liquid is its exceptionally high treatment cost combined with weak cost-effectiveness profiles in payer evaluations. Monthly therapy costs can range from several thousand dollars, with annual expenses exceeding $50,000–$200,000 depending on patient age and dosage . Health technology assessments have indicated that the therapy often fails to meet standard cost-effectiveness thresholds, leading to restricted reimbursement approvals and strict eligibility criteria. For example, insurers may limit coverage to severe cases only, reducing the accessible patient pool. This directly suppresses demand in cost-sensitive regions and delays treatment initiation, ultimately constraining revenue growth and slowing broader market penetration despite clinical benefits.
03

Opportunity: Development of combination therapies leveraging precision medicine and metabolic pathway targeting and Integration into hepatic encephalopathy management protocols within advanced liver care settings

The rise of precision medicine is creating opportunities for combination therapies involving glycerol phenylbutyrate. Research is increasingly focusing on integrating it with gene therapies, enzyme replacement, or microbiome-based treatments to improve metabolic outcomes. This is particularly relevant in rare disease innovation hubs such as the United States and Europe. Clinical-grade liquid formulations are expected to dominate in research-driven applications. Strategic collaborations between biotech firms and academic institutions can accelerate pipeline development. This approach not only enhances therapeutic efficacy but also extends the product lifecycle, creating new revenue streams in highly specialized treatment segments.
Another promising opportunity is the growing use of glycerol phenylbutyrate in managing Hepatic Encephalopathy within specialized liver care centers. As clinical evidence expands, its off-label adoption is increasing in patients with chronic liver disease requiring ammonia control. High-income regions such as North America and Europe are leading this trend, where advanced hospital infrastructure supports combination therapies. The oral liquid format is particularly suitable for long-term outpatient care. Pharmaceutical companies can leverage clinical trials and real-world evidence generation to formalize this application and expand market share beyond traditional metabolic disorder use.
04

Challenge: Limited patient population and rare disease heterogeneity restricting large-scale market expansion potential

Another key restraint is the inherently small and heterogeneous patient population associated with Urea Cycle Disorders, which limits scalability and commercial expansion. As a rare disease, patient numbers remain low, and variability across multiple genetic subtypes complicates standardized treatment approaches and clinical trial design. This fragmentation increases development and commercialization costs while reducing economies of scale. For instance, pharmaceutical companies face challenges in generating large clinical datasets, which can slow regulatory approvals and payer acceptance. Consequently, demand remains concentrated in specialized treatment centers, limiting widespread adoption and creating revenue dependency on a narrow patient base.

Supply Chain Landscape

1

API Production

Lupin LimitedGlobal Pharma TekAmber Lifesciences
2

Drug Manufacturing

AmgenEndo International plcLupin Limited
3

Distribution Supply

McKesson CorporationCardinal HealthAmerisourceBergen
4

End Use Applications

Urea Cycle Disorders TreatmentHepatic Encephalopathy Management
Glycerol Phenylbutyrate Liquid - Supply Chain

Use Cases of Glycerol Phenylbutyrate Liquid in Urea Cycle Disorders Treatment & Hepatic Encephalopathy Management

Urea Cycle Disorders Treatment : Glycerol phenylbutyrate liquid is primarily used as a chronic maintenance therapy for patients diagnosed with Urea Cycle Disorders, where it functions as an effective nitrogen-scavenging agent to control systemic ammonia levels. The liquid oral formulation is widely preferred in pediatric and long-term care settings due to its improved palatability and flexible dosing. It enables sustained ammonia control by facilitating alternative waste nitrogen excretion pathways, reducing the frequency of hyperammonemic crises. Its clinical advantage lies in better tolerability and adherence compared to older therapies, making it a cornerstone treatment in metabolic disorder management across specialized healthcare centers.
Hepatic Encephalopathy Management : In the management of Hepatic Encephalopathy, glycerol phenylbutyrate liquid is used off-label as an adjunct therapy to lower circulating ammonia levels in patients with liver dysfunction. The formulation typically administered is a liquid oral solution, suitable for patients requiring long-term ammonia control alongside standard treatments. It supports the reduction of neurotoxic ammonia accumulation, thereby helping to improve cognitive function and prevent recurrent episodes. Its unique benefit is its targeted mechanism without significant systemic toxicity, which is particularly valuable in chronic liver disease management. Increasing clinical interest is expanding its role in this therapeutic segment.
Research and Development : Glycerol phenylbutyrate liquid is gaining attention in research and development applications, particularly in metabolic and rare disease studies. Researchers primarily utilize clinical-grade liquid formulations to investigate extended indications beyond traditional use in Urea Cycle Disorders. Current studies are exploring its potential in combination therapies, precision medicine approaches, and novel metabolic pathways. The drug’s predictable pharmacokinetics and safety profile make it suitable for controlled trials. Its role in R&D also includes formulation improvements and lifecycle management strategies, supporting pharmaceutical innovation and the development of next-generation ammonia-lowering therapies across global research institutions.

Recent Developments

Recent developments in glycerol phenylbutyrate liquid reflect a clear shift toward market expansion and competitive diversification. In 2025, Endo International plc launched the first generic Ravicti, followed by an authorized generic from Lupin Limited, significantly improving patient access and pricing flexibility . In 2026, regulatory approvals expanded into Middle Eastern markets, strengthening global reach . A key trend is the transition from a single-brand rare disease drug to a multi-player ammonia scavenger therapy market, driving higher adoption in urea cycle disorder management and supporting long-term volume growth.

October 2025 : Endo International plc launched the first FDA-approved generic version of Ravicti (glycerol phenylbutyrate oral liquid) in the U.S. following ANDA approval, marking a major entry into the rare disease generics market.
October 2025 : Lupin Limited launched an authorized generic version of Ravicti in the United States, expanding access through a licensed distribution model tied to the originator supply chain.

Impact of Industry Transitions on the Glycerol Phenylbutyrate Liquid Market

As a core segment of the Pharmaceutical industry, the Glycerol Phenylbutyrate Liquid market develops in line with broader industry shifts. Over recent years, transitions such as Transition from single-originator dominance to emerging multi-player generic competition and Transition toward integrated rare disease care and long-term patient management models have redefined priorities across the Pharmaceutical sector, influencing how the Glycerol Phenylbutyrate Liquid market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from single-originator dominance to emerging multi-player generic competition

The glycerol phenylbutyrate liquid market is transitioning from a highly concentrated, single-originator structure to a more competitive landscape with the entry of generics. Historically dominated by Horizon Therapeutics (now part of Amgen), the market has seen the introduction of authorized and independent generics by Lupin Limited and Endo International plc. This shift is reducing pricing exclusivity and increasing payer negotiating power. As a result, associated industries such as pharmaceutical distribution and specialty pharmacies are adapting to higher volume, lower margin models, while improving patient access across cost-sensitive regions.
02

Transition toward integrated rare disease care and long-term patient management models

Another key transition is the shift from episodic treatment to integrated, lifelong disease management frameworks for conditions like Urea Cycle Disorders. Glycerol phenylbutyrate liquid is increasingly embedded within holistic care pathways that include dietary management, genetic counseling, and digital monitoring tools. This transition is influencing adjacent industries such as telehealth platforms, metabolic clinics, and home healthcare services, which are expanding to support continuous patient engagement. For example, specialized care providers are incorporating ammonia monitoring and adherence tracking solutions, improving outcomes and reducing hospitalizations. This integrated approach is strengthening demand for reliable, patient-friendly formulations and driving collaboration across healthcare ecosystems.